Protego Bio

📍 San Diego, United States👥 24 employees💰 Last funded Dec 2025
Biotechnology Research🌐 protegobio.com
Website LinkedIn
Protego Bio is a clinical-stage company focused on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperone strategy exemplified by tafamidis, which was discovered and developed by our cofounders, Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
1
United States
1
Frequently asked questions
Who invested in Protego Bio?
Protego Bio has 2 investors on record on gritt.io.
When did Protego Bio last raise funding?
The most recent investment in Protego Bio recorded on gritt.io was in December 2025.
What industry is Protego Bio in?
Protego Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Protego Bio based?
Protego Bio is headquartered in San Diego, United States.